Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics, Inc. (BOLT) Healthcare & Pipeline Overview

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in immuno-oncology, developing agents like BDC-1001 and BDC-2034 to treat HER2-expressing solid tumors and other cancers. Their focus on repolarizing the tumor microenvironment through macrophage targeting positions them in a competitive biotech landscape.

What Is the Investment Thesis for BOLT?

Bolt Biotherapeutics presents a high-risk, high-reward investment opportunity within the immuno-oncology space. The company's Boltbody ISAC technology offers a novel approach to cancer treatment by stimulating the immune system to target tumor cells. Key to the investment thesis is the clinical progress of BDC-1001, currently in Phase I/II trials, with potential data readouts in the next 12-18 months serving as a major catalyst. Success in these trials could validate the Boltbody ISAC platform and drive significant value. However, the company's financial position, with a market cap of $8.17M and a negative profit margin of -455.1%, underscores the inherent risks associated with early-stage biotechnology companies. The company's ability to secure additional funding and navigate the complex regulatory landscape will be critical. While the gross margin of 96.9% is promising, it is essential to consider the high R&D expenses typical of the biotech industry. The immuno-oncology field is highly competitive, and the success of Bolt Biotherapeutics depends on its ability to differentiate its therapies and demonstrate clinical efficacy.

Based on FMP financials and quantitative analysis

BOLT Key Highlights

• BDC-1001, a HER2-targeting Boltbody ISAC, is currently in Phase I/II clinical trials, representing a key milestone in the company's clinical development program.
• The company's gross margin stands at 96.9%, indicating strong potential profitability if clinical trials are successful and products are commercialized.
• Bolt Biotherapeutics is developing BDC-2034, a carcinoembryonic antigen (CEA) program targeting colorectal, non-small cell lung, pancreatic, and breast cancers, expanding its therapeutic pipeline.
• The company's market capitalization is $0.01 billion, reflecting its early-stage nature and the inherent risks associated with biotechnology investments.
• Bolt Biotherapeutics is also developing BDC-3042, a Dectin-2 agonist antibody program, to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.

Who Are BOLT's Competitors?

BOLT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BOLT's Key Strengths?

• Proprietary Boltbody ISAC technology platform.
• Clinical-stage pipeline with multiple programs.
• Focus on novel immuno-oncology targets.
• Experienced management team.

What Are BOLT's Weaknesses?

• Limited financial resources.
• Dependence on clinical trial outcomes.
• High R&D expenses.
• Early-stage company with no commercialized products.

What Could Drive BOLT Stock Higher?

• BDC-1001 Phase I/II clinical trial data readouts for HER2-expressing solid tumors.
• Initiation of clinical trials for BDC-2034 in colorectal, non-small cell lung, pancreatic, and breast cancers.
• Continued development and preclinical studies for BDC-3042.
• Potential strategic partnerships with pharmaceutical companies.

What Are the Key Risks for BOLT?

• Financial-distress signal — its Altman Z-Score of -14.92 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for BDC-1001 or other pipeline programs.
• Regulatory delays or rejection of marketing applications.
• Competition from established pharmaceutical companies in the immuno-oncology space.
• Dependence on securing additional funding to support research and development activities.
• Economic downturn affecting investment in biotechnology.

What Are the Growth Opportunities for BOLT?

• BDC-1001 Clinical Advancement: The ongoing Phase I/II clinical trial for BDC-1001 represents a significant growth opportunity for Bolt Biotherapeutics. Positive data readouts from this trial could validate the Boltbody ISAC platform and attract partnerships or further investment. The HER2-expressing solid tumor market is substantial, with a growing need for effective therapies, particularly for HER2-low tumors. The timeline for potential commercialization is dependent on successful trial outcomes and regulatory approvals, potentially within the next 3-5 years.
• BDC-2034 Expansion: The development of BDC-2034, targeting carcinoembryonic antigen (CEA) for colorectal, non-small cell lung, pancreatic, and breast cancers, offers a broad growth avenue. These cancers represent significant unmet medical needs, and a successful therapy could capture a substantial market share. Preclinical and early clinical data will be crucial in determining the potential of BDC-2034, with potential clinical trials expanding over the next 2-3 years.
• BDC-3042 Development: The BDC-3042 program, focused on repolarizing the tumor microenvironment by targeting macrophages, presents a novel approach to cancer immunotherapy. This strategy could enhance the effectiveness of other cancer therapies and address tumors that are resistant to current treatments. The market for therapies targeting the tumor microenvironment is growing, with increasing recognition of its importance in cancer progression. Clinical development of BDC-3042 is expected to advance over the next several years.
• Strategic Partnerships: Bolt Biotherapeutics has the opportunity to form strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its therapies. These partnerships could provide access to additional funding, expertise, and resources, enhancing the company's ability to bring its products to market. The timeline for potential partnerships is uncertain but could occur at any stage of clinical development.
• Expansion into New Targets: Bolt Biotherapeutics can leverage its Boltbody ISAC platform to develop therapies targeting new cancer antigens and tumor types. This expansion would broaden the company's pipeline and reduce its reliance on its current lead programs. The immuno-oncology field is constantly evolving, with new targets being identified regularly, providing opportunities for Bolt Biotherapeutics to innovate and expand its therapeutic offerings. Research and development efforts in this area are ongoing.

What Opportunities Does BOLT Have?

• Strategic partnerships with larger pharmaceutical companies.
• Expansion into new cancer targets and indications.
• Positive clinical data readouts.
• Advancements in immuno-oncology research.

What Threats Does BOLT Face?

• Competition from established pharmaceutical companies.
• Regulatory hurdles and delays.
• Clinical trial failures.
• Economic downturn affecting investment in biotechnology.

What Are BOLT's Competitive Advantages?

• Proprietary Boltbody™ Immune-Stimulating Antibody Conjugates (ISACs) platform.
• Clinical-stage pipeline with promising early results.
• Experienced management team with expertise in immuno-oncology.
• Focus on novel targets and mechanisms of action.

What Does BOLT Do?

Bolt Biotherapeutics, Inc., founded in 2015 and headquartered in Redwood City, California, is a clinical-stage biotechnology company dedicated to developing a new generation of immuno-oncology therapeutics. The company's core mission revolves around harnessing the power of the immune system to target and eliminate tumor cells. Bolt Biotherapeutics is pioneering the development of Boltbody™ Immune-Stimulating Antibody Conjugates (ISACs), a proprietary technology platform designed to stimulate the immune system to recognize and destroy cancer cells. The company's lead product candidate, BDC-1001, is a HER2-targeting Boltbody ISAC currently in Phase I/II clinical trials for patients with HER2-expressing solid tumors, including HER2-low tumors. This innovative therapy aims to redirect the immune system to attack HER2-expressing cancer cells, offering a potential treatment option for patients who may not respond well to existing therapies. In addition to BDC-1001, Bolt Biotherapeutics is also advancing BDC-2034, a carcinoembryonic antigen (CEA) program targeting colorectal, non-small cell lung, pancreatic, and breast cancers. Furthermore, BDC-3042, a Dectin-2 agonist antibody program, is being developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. The company is also exploring a programmed cell death-ligand 1 (PD-L1) program for tumors that are nonresponsive to immune checkpoint blockade, expanding its portfolio of potential cancer treatments. Bolt Biotherapeutics operates primarily in the United States, focusing on research and development activities to advance its pipeline of immuno-oncology agents. The company's strategy involves identifying novel targets and developing innovative therapies that can address unmet medical needs in cancer treatment. By leveraging its Boltbody ISAC platform and focusing on specific tumor microenvironments, Bolt Biotherapeutics aims to create more effective and targeted cancer therapies.

What Products and Services Does BOLT Offer?

• Develop immuno-oncology agents to target tumor cells.
• Utilize the Boltbody™ Immune-Stimulating Antibody Conjugates (ISACs) platform.
• Conduct Phase I/II clinical trials for BDC-1001, a HER2-targeting therapy.
• Develop BDC-2034, a carcinoembryonic antigen (CEA) program.
• Create BDC-3042, a Dectin-2 agonist antibody program.
• Explore programmed cell death-ligand 1 (PD-L1) program.

How Does BOLT Make Money?

• Develop and license immuno-oncology agents.
• Generate revenue through partnerships and collaborations.
• Focus on clinical trials to demonstrate efficacy and safety.
• Seek regulatory approvals for commercialization.

What Industry Does BOLT Operate In?

Bolt Biotherapeutics operates within the rapidly evolving immuno-oncology sector, a segment of the biotechnology industry focused on developing therapies that harness the body's immune system to fight cancer. The market is characterized by intense competition, with numerous companies, ranging from large pharmaceutical firms to smaller biotechs, vying to develop innovative cancer treatments. The global immuno-oncology market is projected to reach billions of dollars by 2030, driven by the increasing prevalence of cancer and the demand for more effective and less toxic therapies. Bolt Biotherapeutics aims to differentiate itself through its Boltbody ISAC platform, which offers a unique approach to stimulating the immune system to target tumor cells. Success in this competitive landscape hinges on demonstrating clinical efficacy and securing regulatory approvals for its pipeline of immuno-oncology agents.

Who Are BOLT's Key Customers?

• Patients with HER2-expressing solid tumors.
• Patients with colorectal, non-small cell lung, pancreatic, and breast cancers.
• Healthcare providers prescribing cancer therapies.
• Pharmaceutical companies seeking to expand their oncology portfolios.

FY2026 estForward Outlook

Wall Street analysts project Bolt Biotherapeutics, Inc. revenue of about $1.1M for fiscal 2026, with EPS near $-15.88.

Quarterly Financial Performance: Bolt Biotherapeutics, Inc.

Revenue for Bolt Biotherapeutics, Inc. came in at $26K during Q1 2026, a 99.0% contraction versus the preceding quarter. The company recorded a net loss of $7.2M, with diluted EPS of $-3.87. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BOLT averaged $-3.97 in diluted EPS.

BOLT Valuation & Market Position

With a $8.17M market cap, Bolt Biotherapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, BOLT's quantitative score of 18/100 is below the peer average of 70/100.

Key Financial Metrics

Return on assets is -61.6%, showing how much profit it generates from its asset base. A current ratio of 3.51 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 3/9Financial Health

Bolt Biotherapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.92 places it in the distress zone, a signal of elevated financial risk.

Company Profile

Bolt Biotherapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO William Quinn. BOLT has traded publicly since 2021.

BOLT Financials

BOLT Latest News

BOLT Analyst Consensus

BOLT MoonshotScore

Bolt Biotherapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources